

Benign Prostatic Hyperplasia Drugs Market Size, Trends, Analysis, and Outlook By Drug (Alpha-Blockers, 5-Alpha Reductase Inhibitors, Alpha-Adrenergic Blockers, Phosphodiesterase Type-5 Inhibitors, Beta-Blockers, Others), By Dosage (Tablet, Capsule, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/B58FAE64CBC0EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: B58FAE64CBC0EN

Abstracts

The global Benign Prostatic Hyperplasia Drugs market size is poised to register 6.5% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Benign Prostatic Hyperplasia Drugs market By Drug (Alpha-Blockers, 5-Alpha Reductase Inhibitors, Alpha-Adrenergic Blockers, Phosphodiesterase Type-5 Inhibitors, Beta-Blockers, Others), By Dosage (Tablet, Capsule, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).

In the market for benign prostatic hyperplasia drugs, there's a growing focus on developing novel pharmacotherapeutic agents with improved efficacy and safety profiles. Pharmaceutical companies are exploring innovative mechanisms of action, such as selective α_1 -adrenergic receptor antagonism and 5-alpha reductase inhibition, to alleviate lower urinary tract symptoms while minimizing adverse effects on sexual function. Additionally, the pursuit of combination therapies targeting multiple pathophysiological pathways holds promise for enhancing treatment outcomes and reducing the need for invasive procedures in patients with symptomatic BPH..

Benign Prostatic Hyperplasia Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Benign Prostatic Hyperplasia Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Benign Prostatic Hyperplasia Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Benign Prostatic Hyperplasia Drugs industry.

Key market trends defining the global Benign Prostatic Hyperplasia Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Benign Prostatic Hyperplasia Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Benign Prostatic Hyperplasia Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Benign Prostatic Hyperplasia Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Benign Prostatic Hyperplasia Drugs industry

Leading Benign Prostatic Hyperplasia Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Benign Prostatic Hyperplasia

Drugs companies.

Benign Prostatic Hyperplasia Drugs Market Study- Strategic Analysis Review

The Benign Prostatic Hyperplasia Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Benign Prostatic Hyperplasia Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Benign Prostatic Hyperplasia Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Benign Prostatic Hyperplasia Drugs Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Benign Prostatic Hyperplasia Drugs Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Benign Prostatic Hyperplasia Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Benign Prostatic Hyperplasia Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Benign Prostatic Hyperplasia Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Benign Prostatic Hyperplasia Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Benign Prostatic Hyperplasia Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Benign Prostatic Hyperplasia Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Benign Prostatic Hyperplasia Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Benign Prostatic Hyperplasia Drugs in Asia Pacific. In particular, China, India, and South East Asian Benign Prostatic Hyperplasia Drugs markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in

the region.

Latin America Benign Prostatic Hyperplasia Drugs Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Benign Prostatic Hyperplasia Drugs Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Benign Prostatic Hyperplasia Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Benign Prostatic Hyperplasia Drugs.

Benign Prostatic Hyperplasia Drugs Market Company Profiles

The global Benign Prostatic Hyperplasia Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Aeterna Zentaris, Allergan, Astellas Pharma Inc, Bausch Health Companies Inc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., GemVax & KAEL and Kissei Pharmaceutical Co. Ltd, GlaxoSmithKline plc, IntelGenx Corp, Ipsen Pharma, Kaken Pharmaceutical Co. Ltd, Lilly, Merck Sharp & Dohme Corp, Novartis AG, Nymox Pharmaceuticals Corp, Pfizer Inc, Quest PharmaTech Inc, Sanofi, Teva Pharmaceutical Industries Ltd.

Recent Benign Prostatic Hyperplasia Drugs Market Developments

The global Benign Prostatic Hyperplasia Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Benign Prostatic Hyperplasia Drugs Market Report Scope

Benign Prostatic Hyperplasia Drugs Market Size, Trends, Analysis, and Outlook By Drug (Alpha-Blockers, 5-Alpha...

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Aeterna Zentaris

Allergan

Astellas Pharma Inc

Bausch Health Companies Inc

Bayer AG

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co.

GemVax & KAEL and Kissei Pharmaceutical Co. Ltd

GlaxoSmithKline plc

IntelGenx Corp

Ipsen Pharma

Kaken Pharmaceutical Co. Ltd

Lilly

Merck Sharp & Dohme Corp

Novartis AG

Nymox Pharmaceuticals Corp

Pfizer Inc

Quest PharmaTech Inc

Sanofi

Teva Pharmaceutical Industries Ltd

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Benign Prostatic Hyperplasia Drugs Market Overview and Key Findings, 2024
- 1.2 Benign Prostatic Hyperplasia Drugs Market Size and Growth Outlook, 2021- 2030
- 1.3 Benign Prostatic Hyperplasia Drugs Market Growth Opportunities to 2030
- 1.4 Key Benign Prostatic Hyperplasia Drugs Market Trends and Challenges
 - 1.4.1 Benign Prostatic Hyperplasia Drugs Market Drivers and Trends
 - 1.4.2 Benign Prostatic Hyperplasia Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Benign Prostatic Hyperplasia Drugs Companies

2. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET SIZE OUTLOOK TO 2030

- 2.1 Benign Prostatic Hyperplasia Drugs Market Size Outlook, USD Million, 2021- 2030
- 2.2 Benign Prostatic Hyperplasia Drugs Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
 - By Type

Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Benign Prostatic Hyperplasia Drugs Market, 2025
5.2 Asia Pacific Benign Prostatic Hyperplasia Drugs Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Benign Prostatic Hyperplasia Drugs Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Benign Prostatic Hyperplasia Drugs Market, 2025
5.5 Europe Benign Prostatic Hyperplasia Drugs Market Size Outlook by Type, 2021- 2030
5.6 Europe Benign Prostatic Hyperplasia Drugs Market Size Outlook by Application,

2021- 2030

5.7 Key Findings for North America Benign Prostatic Hyperplasia Drugs Market, 2025

5.8 North America Benign Prostatic Hyperplasia Drugs Market Size Outlook by Type, 2021- 2030

5.9 North America Benign Prostatic Hyperplasia Drugs Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Benign Prostatic Hyperplasia Drugs Market, 2025

5.11 South America Pacific Benign Prostatic Hyperplasia Drugs Market Size Outlook by Type, 2021- 2030

5.12 South America Benign Prostatic Hyperplasia Drugs Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Benign Prostatic Hyperplasia Drugs Market, 2025

5.14 Middle East Africa Benign Prostatic Hyperplasia Drugs Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Benign Prostatic Hyperplasia Drugs Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

6.1 US Benign Prostatic Hyperplasia Drugs Market Size Outlook and Revenue Growth Forecasts

6.2 US Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

6.16 Italy Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts

6.18 Rest of Europe Benign Prostatic Hyperplasia Drugs Industry Drivers and

Opportunities

- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Benign Prostatic Hyperplasia Drugs Industry Drivers and Opportunities

7. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. BENIGN PROSTATIC HYPERPLASIA DRUGS COMPANY PROFILES

8.1 Profiles of Leading Benign Prostatic Hyperplasia Drugs Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Aeterna Zentaris

Allergan

Astellas Pharma Inc

Bausch Health Companies Inc

Bayer AG

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co.

GemVax & KAEL and Kissei Pharmaceutical Co. Ltd

GlaxoSmithKline plc

IntelGenx Corp

Ipsen Pharma

Kaken Pharmaceutical Co. Ltd

Lilly

Merck Sharp & Dohme Corp

Novartis AG

Nymox Pharmaceuticals Corp

Pfizer Inc

Quest PharmaTech Inc

Sanofi

Teva Pharmaceutical Industries Ltd

9. APPENDIX

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

I would like to order

Product name: Benign Prostatic Hyperplasia Drugs Market Size, Trends, Analysis, and Outlook By Drug (Alpha-Blockers, 5-Alpha Reductase Inhibitors, Alpha-Adrenergic Blockers, Phosphodiesterase Type-5 Inhibitors, Beta-Blockers, Others), By Dosage (Tablet, Capsule, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/B58FAE64CBC0EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B58FAE64CBC0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970